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Approximately 40,000 women will die from breast cancer in the United States in 2014. 
About 90% of these deaths will be due to metastases, rather than the primary tumor and majority 
of metastases are due to the recurrence and progression of non-metastatic disease. Current 
adjuvant treatments, such as chemotherapy and radiation, have severe side effects and may result 
in overtreatment and drug resistance.  
Since greater than 90% of patients are diagnosed between stages I-III and have minimal 
residual disease after treatment, there is an opportunity to treat patients with an autologous breast 
cancer vaccine.  Autologous vaccines under development have a multivalent antigen repertoire, 
nontoxic side effects and most importantly, allow for personalized, patient specific treatment.  A 
vaccine may be able to eliminate remaining tumor cells following primary treatment, prevent a 
recurrence and result in improved survival. 
We developed an autologous breast cancer vaccine using two murine cell lines, 4T1 and 
EMT6, to demonstrate the potential of vaccines for adjuvant treatment of breast cancer.  We first 
tested two commonly used methods of inactivating cells, irradiation and freeze/thaw cycling, to 
see if either method was superior in establishing protective immunity.  Next, we measured 
surface expression of MHC I, MHC II, Fas, ICAM-1, B7-1 and B7-2 and secretion of the 
immunosuppressive cytokines GM-CSF, IL-6, MCP-1, TGF-β, and VEGF by each cell line to 
better understand differences in immunogenicity.   
In the EMT6 model, vaccination with irradiated cells provided protection from live tumor 
challenge in 80% of mice, while no protection was seen following vaccination with 
freeze/thawed cells. Furthermore, a minimum threshold of 250,000 irradiated cells was needed to 




freeze/thawed vaccines.  After measurement of surface molecules, B7-1 was up-regulated 
following irradiation in EMT6 cells, but not 4T1 cells.  IFN-γ was used to up-regulate surface 
markers on 4T1 cells.  Additionally, EMT6 cells secreted higher levels of IL-6, MCP-1, TGF-β, 
and VEGF, while 4T1 cells secreted higher levels of GM-CSF.  Expression of B7-1 and GM-
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Chapter 1: Introduction to Breast Cancer 
Diagnosis and Staging 
 About 295,240 women will be diagnosed with breast cancer in the United States in 2014.  
Majority of these cases, about 232,670, will be invasive breast cancer, while the other 62,570 
cases will be carcinoma in situ, or pre-cancer.  In addition to being the most diagnosed cancer, 
breast cancer is the second leading cause of cancer death in women.  In 2014, about 40,000 
women will die from breast cancer.  Once a woman is diagnosed with breast cancer, the cancer is 
given a stage based on extent of disease. The cancer stage is one of the critical factors in 
determining prognosis and treatment.  Staging of a cancer is evaluated on size of the primary 
tumor (T), number of nearby lymph nodes involved (N), and presence of metastasis (M).  This is 
called the TNM system.  The category T is divided into 4 subcategories: T1 is 2 cm or less in 
diameter, T2 is between 2 cm and 5 cm, T3 is more than 5 cm, and T4 is a tumor of any size 
growing into the chest wall or skin.  The category N is also divided into 4 subcategories: N0 is 
no presence of tumor cells in lymph nodes, N1 is cancer has spread to 1-3 underarm lymph nodes 
and/or micrometastases in the internal mammary lymph nodes (N1mi), N2 is cancer has spread 
to 4-9 underarm lymph nodes or has enlarged mammary lymph nodes, and N3 is cancer has 
spread to 10 or more underarm lymph nodes with one area greater than 2 mm or cancer has 
spread to 4 underarm lymph nodes with one area greater than 2 mm and cancer is found in 
internal mammary lymph nodes.  The category M is divided into two subgroups: the absence of 
metastatic disease (M0) or the presence of metastatic disease (M1)
1
.   
Information from the T, N and M categories are combined and given a single stage 
grouping.  The stage ranges from Stage I (least advanced) to Stage IV (most advanced).  A 




carcinoma in situ (DCIS) and is considered pre-cancer.  The TNM system is combined to the 
stage group as follows: 
Stage I: T1, N0, M0 
  T0 or T1, N1mi, M0 
Stage II: T0 or T1, N1, M0 
   T2 or T3, N0, M0 
   T2, N1, M0 
Stage III: T0 to T2, N2, M0 
     T3, N1 or N2, M0 
     T4, N0 to N2, M0 
Stage IV: any T, any N, M1 
 In general, an increase in the T, N, and M categories correlate with more advanced stage, 
but as soon as distant metastases are present the cancer is Stage IV
1
.  Majority of patients are 
diagnosed with cancer between Stage 0 and Stage II.  Approximately 20.3%, 41.4%, 23.8% of 
women are diagnosed with Stage 0, I, or II, respectively.  Only 8.3% of women are diagnosed 
with Stage III cancer and 3.9% of women are diagnosed with Stage IV cancer
2
.  Considering that 
early diagnosis of breast cancer is critical for survival, it is beneficial that most breast cancer 
patients are diagnosed at an earlier stage. As the number of tumor cells spreading through nearby 
lymph nodes and establishing in distant organs increases, the harder the cancer is to eliminate, 
which is why early diagnosis of breast cancer is key.  For example, the relative 5 year survival 
rate for breast cancer patients is 100%, 93%, 72% and 22% for Stage I, II, III and IV, 
respectively
1
.  The low survival rate for stage IV disease is directly related to the establishment 





 In addition to staging of breast cancer, presence of the hormone receptors, estrogen 
receptor (ER) and progesterone receptor (PR) and human epidermal growth factor receptor 
(HER2/neu) is also considered when giving a prognosis and treatment.  Breast cancers can be 
divided into 4 subtypes: luminal A, luminal B, triple negative and HER2 type.  The most 
common subtype is luminal A, which has presence of one or both hormone receptors and is 
HER2 negative.  Luminal B contains one or both hormone receptors and is HER2 positive.  
Triple-negative subtype lacks all three receptors, while the HER2 subtype only expresses the 
HER2 and no hormone receptors
3
.   
Luminal tumors look most like the cells (luminal cells) on the inner lining of mammary 
ducts and are the most frequently diagnosed accounting for 40% (Luminal A) and 20% (Luminal 
B) of all diagnoses.  Of all of the subtypes, luminal A usually has the best prognosis.  Compared 
to luminal A, luminal B is associated with having larger tumors or positive lymph nodes.  The 
prevalence of TNBC and HER2 type ranges from 15-20% and 10-15% of all diagnosed breast 
cancers, respectively.  Both triple negative and HER2 type are often aggressive and associated 
with recurrence and metastases.  The receptor status of each tumor must be considered when 
treating breast cancer patients because some treatments, like hormone or targeted therapy, will 





 The primary treatment of breast cancer is surgery and is usually followed by adjuvant 
therapy including chemotherapy, radiation, hormone therapy and/or targeted therapy.   Surgery 




removal of the tumor and surrounding tissue, called a lumpectomy, or removal of up to a quarter 
of the breast, called a quadrantectomy.  After tissue removal, edges of the tumor are examined by 
a pathologist for presence of tumor cells. If tumor cells are not found, the tissue has “negative 
margins” and no further surgery may be needed.  If tumor cells are found, the tissue has “positive 
margins” and tumor cells may have been left behind.  The surgeon may go back to remove more 
tissue or perform a mastectomy.  Mastectomy involves whole breast removal, and possibly 
nearby tissues such as underarm lymph nodes and chest muscles behind the breast.  A few lymph 
nodes may be resected during primary surgery or a biopsy may be performed to check for 
presence of cancer cells.  Analysis of lymph nodes is important to determine the stage of breast 
cancer and potential treatment following surgery
1
.  
After surgery if no cancer is detectable, then patients are usually given adjuvant therapy 
in an effort to prevent a recurrence.  It is thought that early in tumor development tumor cells 
leave the primary tumor and begin to spread throughout the body.  Although these cells exist, 
they are undetectable and may begin to replicate and establish a second tumor elsewhere in the 
body.  Adjuvant therapy is given in an effort to eliminate these lingering tumor cells following 
surgery.  Chemotherapy is a systemic therapy given to approximately 80% of patients to 
eliminate tumor cells that have migrated from the tumor
4
.  In advanced stage patients, 
chemotherapy may be the main treatment modality.  Chemotherapy works by attacking quickly 
dividing tumor cells, but in addition attacks noncancerous quickly dividing cells such as those 
from our bone marrow, hair follicles, and lining of our mouth.  This results in side effects such as 
hair loss, mouth sores, low blood cell counts along with toxic side effects like neuropathy, heart 
damage and “chemo-brain”.  Radiation therapy is a local treatment given at the tumor site.  In 




come back in the breast or nearby lymph nodes.  After a mastectomy, radiation treatment may be 
given if the tumor was larger than 5 cm or if cancer cells were found in the lymph nodes
1
.   
Hormonal therapy, such as Tamoxifen, may also be given as an adjuvant therapy to breast 
cancer patients.  Estrogen promotes the growth of cancers that is hormone-receptor positive and 
hormonal therapy either lowering estrogen from acting on the cancer or lowering estrogen levels.  
Side effects of tamoxifen include fatigue, hot flashes, mood swings and possibly more severe 
side effects such as secondary cancers of the uterus and blood clots.  However, this therapy is 
only given for hormone receptor positive tumors.  Similar to hormonal therapy, targeted therapy, 
such as trastuzumab (Herceptin), relies on the presence of HER2 on the surface of tumor cells.  
Elevated HER2 expression is associated with an aggressive growing and spreading tumor
1
. 
Trastuzumab attempts to slow down cancer growth by use of a monoclonal antibody targeting 
HER2 to block the cell from receiving growth signals
1
.  Compared to chemotherapy, side effects 
aren’t as severe and include fever, chills, weakness, nausea and vomiting with a potential severe 
side effect of heart failure. 
Some patients may receive chemotherapy or hormonal therapy prior to surgery, which is 
called neoadjuvant therapy. The goal of neoadjuvant therapy is to shrink the tumor and allow for 






 After treatment, if not all cancer cells are eliminated, the cancer may come back either 
locally or distantly (metastases) and this is called a recurrence.  A local recurrence may come 




recurrence is similar to treatment of the primary tumor.  If the patient originally had a 
lumpectomy, often the patient undergoes a mastectomy and receives some sort of adjuvant 
therapy.  If the patient originally had a mastectomy, the secondary tumor is removed and often 
followed with radiation and/or other adjuvant therapies
1
.   
Distant recurrences most often occur in the bones, lung, liver or brain.  Treatment after a 
diagnosis of metastases focuses more on the length and quality of life of the patient, rather than 
removing the cancer using the same therapies used to treat the primary tumor.  Although 
metastatic cancer is treatable, it is not curable
1
.  
The possibility of a recurrence depends on a few different factors including the number of 
positive lymph nodes at the time of primary surgery and the breast cancer subtype.  For stages I, 
II, and III the recurrences rates after 5 years are 6.9%, 11.2% and 12.7%, respectively.  After 10 
years, the recurrence rates increase to about 20%
5
.  Additionally, a greater chance of recurrence 
is associated with more aggressive tumors, such as TNBC.  For example, 6 years after diagnosis 
almost a third of TNBC patients have a recurrence compared to only 10% of all breast cancer 
patients.  TNBC patients divided into their cancer stage at diagnosis show a distinct increase in 
recurrence corresponding with a higher cancer stage.  The prevalence of recurrence 5 years after 
diagnosis in TNBC patients is about 7%, 33%, and 60% for stages I, II and III, respectively
6
.   As 
evident by these statistics, an increase in recurrence is associated with extent of disease at time of 
diagnosis and more aggressive breast cancer subtypes.   
Since 90% of breast cancer deaths are due to metastases
7
 and only 3.9% of patients are 
diagnosed with stage IV cancer
1
, majority of breast cancer deaths are due to the recurrence of 




following surgery in an effort to decrease breast cancer recurrence, and therefore increase 
survival rate.  
 
Objective 
The overall objective of this project was to develop and characterize an autologous tumor 
cell vaccine using a murine model that may be able to prevent recurrences and therefore result in 
improved overall survival.  An autologous tumor cell vaccine is a form of active specific 
immunotherapy (ASI) that utilizes inactivated patient specific tumor cells to launch an anti-
tumor immune response.  Active stimulation of the immune system is one advantage of an 
autologous vaccine over current passive targeted therapies.  By using patient-specific tumor 
cells, numerous known and unknown antigens may be targeted at once ensuring a personalized 
and potentially polyclonal immune response with minimal toxicity.  
In this study, we used two murine breast cancer cells lines, 4T1 and EMT6, to develop an 
autologous vaccine.  Both cell lines were used in order to compare their inherent immunogenic 
qualities relating to the vaccine and in vitro characterization.  The 4T1 cell line is known as a 
non-immunogenic cancer representing human stage IV breast cancer, while the EMT6 cell line is 
relatively immunogenic.  For each cell line, we first pursued the most immunogenic way to 
inactivate tumor cells.  Two commonly used methods were used to inactivate cells, irradiation 
and freeze/thaw, and given as prophylactic vaccines to see if there was any difference in 
protection after a challenge with live tumor cells.  An immunogenic profile was then created for 
each cell line based on surface molecule expression and immunosuppressive cytokine secretion.  
These are two characteristics that tumors use to evade the immune system, specifically T 




each cell line.  Based on the differences, an immunogenic tumor may be engineered from a non-
immunogenic tumor by manipulating various immunogenic characteristics and therefore promote 
an anti-tumor immune response.  
 
Chapter 2: Autologous Whole Tumor Cell Vaccines for Breast Cancer 
Introduction 
Approximately 232,570 women will be diagnosed with invasive breast cancer and 40,000 
women will die from breast cancer in the United States in 2014
1
.  However, 90% of breast cancer 
deaths are due to metastases to the bone, brain, lung and liver, not the primary tumor
7
.  
Considering only 3.9% of breast cancer patients are diagnosed with metastatic Stage IV cancer, 
majority of these metastases and deaths are due to the recurrence and progression of non-
metastatic disease
2
.  For example, 7% of Stage I patients will experience tumor recurrence after 5 
years, while 11% and 13% of patients with Stage II and Stage III, respectively will experience 
tumor recurrence. After 10 years, the overall breast cancer recurrence rate is about 20%
5
. 
In an effort to combat tumor recurrence, majority of patients receive adjuvant therapy 
such as chemotherapy and/or radiation. Chemotherapy is routinely offered to about 80% of 
patients
4
 even though the benefits are limited especially in older patients. Following 
chemotherapy treatment, patients younger than 50 years of age increase their 5 year survival rate 
by 4.7% while only a 2.6% increase is seen in patients older than 50
8
.  Chemotherapy normally 
includes a combination of drugs, such as anthracyclines or taxanes, and has toxic side effects 
including hair loss, mouth sores, low blood cell counts, neuropathy and “chemo-brain”
1
.  
Radiation is also used an as adjuvant to treat breast cancer patients. A meta-analysis showed only 
a 5% decrease in 15-year breast cancer mortality risk 
9




radiation can occur either by treating patients that do not need adjuvant therapy or administration 
of more aggressive treatment than necessary. A recent estimate suggests that 1 to 3 deaths occur 
due to overtreatment for every breast cancer death evaded 
10
. Although chemotherapy and 
radiation increases survival rate for breast cancer patients, it comes with severe side effects, 
overtreatment results in unnecessary deaths and 1 in 5 patients still have a recurrence after 10 
years.  These recurrences result after adjuvant therapy due to the inability to eliminate all hidden 
tumor cells and may then acquire drug resistance 
11, 12
.  Due to severe side effects, overtreatment, 
and drug resistance with current adjuvant therapies there is a need for more effective 
interventions to limit recurrence and progression.  
In 2010, the FDA approved sipuleucel-T (Provenge), an active cellular immunotherapy 
for the treatment of advanced prostate cancer. Since then, there has been a movement towards 
research of active specific immunotherapies (ASI) for the treatment of cancer.  ASI is the use of 
tumor specific antigens to stimulate the adaptive immune system and launch an immune 
response against a tumor.  In theory, after exposure to tumor antigens, tumor specific 
lymphocytes would be able eradicate all tumor cells and establish an immune memory.  Breast 
cancer would be an ideal disease for the use of ASI due to the delay of recurrence after treatment 
and the thousands of patients eligible for this therapy. The time period before a recurrence would 
allow the immune system time to be stimulated by ASI, activate T lymphocytes to eradicate 
residual disease, and memory T lymphocytes to maintain immune memory of breast cancer. 
Since greater than 90% of patients are diagnosed between stages I-III and have minimal residual 
disease after treatment, ASI has the potential to benefit thousands of breast cancer patients from 




ASI can be accomplished using different vaccine formulations classified by the form of 
antigen and how they are administered. Antigens can be presented to the immune system as 
whole tumor cells 
13





or cell lysates 
17
. In addition, antigens can be delivered as inactivated whole cells 
18, 19
, pulsed 
with dendritic cells 
20, 21




Advantages of Autologous Tumor Cell Vaccines 
Autologous tumor cells have a number of advantages when used as ASI, including having 
a multivalent antigen repertoire and patient specificity. An ideal cancer antigen has 
immunogenicity, oncogenicity, and specificity.  Out of 75 cancer antigens analyzed by Cheever 
et al., none of the antigens satisfied all criteria for an ideal cancer antigen 
23
.  However, by using 
many antigens, both known and unknown, the ideal cancer antigen criteria may be satisfied 
among all of the available antigens to allow a higher immune system response. Additionally, by 
using autologous cells all potential antigens are being shown to the immune system. More than 
one potential antigen can be targeted at once, eliminating the problem of antigen loss and 
potentially activating a polyclonal immune response 
13, 22
.   Importantly, all of the potential 
antigens are directly from the patient’s own tumor, therefore ensuring that patients are exposed 
to the antigens that their own tumor expresses 
13
.  There are an estimated 105 mutant genes in 
breast cancer and a personalized approach can be taken to ensure these mutations are recognized 
by a patient’s immune system 
24
.  These inactivated whole tumor cells could enable a patient’s 
own immune system to specifically destroy remaining cancer cells left after surgery and prevent 
the development of recurrence 
25




Furthermore, autologous whole tumor cells may be beneficial to even the aggressive 
triple negative breast cancer (TNBC). TNBC is a lethal subtype of breast cancer that has a 
greater risk of recurrence and shortened survival compared to hormone positive subtypes and has 
a 5 year survival of ~90%, ~78%, and ~35%, for stage I, stage II, and stage III-IV, respectively 
26
.  However, poor survival of TNBC can be partly explained by limited treatment options since 
hormonal and HER2 treatments do not benefit TNBC patients.  By inactivating whole TNBC 
tumor cells, expression of current unknown antigens may be presented to the immune system and 
elicit a patient-specific adaptive immune response.   
 
Disadvantages of Autologous Tumor Cell Vaccines 
Preclinical and clinical studies have presented some challenges with development of 
autologous tumor cell vaccines.  First, harvesting enough tumor cells can be inefficient and time 
consuming 
13
. In a study by Avigan in 2004, only 16 of 32 vaccines were successfully generated. 
Vaccines were composed of fusions of dendritic cells and tumor cells which were then irradiated. 
Tumor cells did not expand ex vivo and tumor tissue smaller than 1cm did not provide adequate 
cell yields 
27




. The differences in tumor cell yield may be due to a lack of standardization of autologous 
tumor vaccine preparations which does not allow comparable results 
29
.  Tumors can be 
dissociated and then inactivated in a variety of ways. Tumors can be dissociated enzymatically 
with collagenase and DNAse 
28
, mechanically, or both 
30
.  Once in a single-cell suspension, 




 or mitomycin-C 
28
.  




suspension, others do not 
28, 31-33
. It is uncertain which method(s) induces the most immunogenic 
vaccine.  
Furthermore, tumor cells are mainly composed of normal antigens 
22
. The tumor antigens 
present are only mildly immunogenic and self-like, therefore the immune response is not strong. 
Also, tumor cells do not express enough costimulatory proteins to produce a significant response 
25
.  Delivery systems and adjuvants are under exploration to increase immunogenicity. 
 
Clinical trials with Autologous Breast Cancer Vaccines 
To our knowledge, there have only been four clinical trials exploring autologous breast 
cancer tumor cell vaccines, two of which are ongoing.  Majority of the clinical trials involving 
autologous vaccines for any cancer have only been phase I/II trials with small numbers of 
advanced stage patients. These patients have larger, metastatic tumors that secrete 
immunosuppressive factors and a poor immune status 
34
. Since tumor cells alone have shown to 
be poorly immunogenic, there has been no trial testing of autologous cells alone. Instead, several 
trials using transfected autologous tumor cells have been explored. Autologous cells have often 
been genetically modified to express cytokines, chemokines or costimulatory molecules in order 
to make the vaccine more immunogenic 
13
. GM-CSF has shown to be an effective costimulatory 
cytokine due to its ability to activate a tumor targeted T cell response by recruitment of dendritic 
cells. The dendritic cells are then able to uptake, process and present the antigen 
13
. Although 
GM-CSF has been used as an immune adjuvant, if given at high doses over a sustained period of 
time it can cause immunosuppression by recruitment of MDSCs. A minimal dose to achieve 






There are currently two active clinical trials registered in the NIH Clinical Trial database 
investigating autologous breast cancer cells that have been engineered to express GM-CSF. Both 
are phase I/II trials sponsored and collaborated by Dana-Farber Cancer Institute and Brigham 
and Women’s Hospital. One trial is strictly for metastatic breast cancer patients
36
, while the other 
is for breast cancer stages II-III
37
.  The study completion date for metastatic patients is January 
2015 and the study completion date for stages II-III is April 2015 with a primary completion date 
of April 2014.  
A study conducted by Ahlert et al.
33
 explores a vaccine comprised of autologous breast 
tumor cells infected with Newcastle disease virus (NDV). Primary breast cancer and metastatic 
breast cancer patients were treated with an autologous tumor cell vaccine infected with non-lytic 
NDV. Primary breast cancer patients started immunotherapy following surgery and were given at 
least two vaccinations.  If applicable, chemotherapy and radiation was administered 28-35 days 
after the start of immunotherapy. Metastatic breast cancer patients followed this same protocol 
with the addition of IL-2/IFNα-2a and anti-suppressive drugs, such as cyclophosphamide and 
epirubicin.  Vaccine quality was divided into high and low quality. The high quality group had a 
median count of 1.5x10
6
 viable tumor cells for each vaccine and median viability greater than 
33%. The low quality group did not meet one of these qualifications. After 4 years, a significant 
difference was seen in patients with primary breast cancer: 96% of patients with a high vaccine 
quality were alive compared to 68% with a lower vaccine quality.  An increase in survival was 
also observed in metastatic breast cancer patients with a high quality vaccine compared to a low 
quality vaccine, although the difference was not significant (P= 0.18) due to low patient 
numbers. 
33




results.  This study also represents the importance of developing and standardizing vaccine 
preparations. 
In a study using autologous cells with other antigens, Elliott and Head
28
 used a 
vaccination with autologous breast tumor cells, allogeneic breast tumor cells, and 3 antigens 
combined with IL-2 and GM-CSF given to patients with depressed lymphocyte immunity.  All 
patients underwent surgery and were finished with chemotherapy and/or radiation treatment prior 
to immunotherapy.  Immunocompetency was determined at least 10 weeks after completion of 
adjuvant therapy and evaluated host reactivity to tumor antigens.   Patients with depressed 
lymphocyte immunity were given a total of 6 vaccines on weeks 1, 2, 3, 7, 11 and 15.  They 
concluded that disease specific survival of vaccinated patients with depressed immunity (89%) 
was significantly different than patients with depressed immunity that were unvaccinated (59%) 
28
.   
 
Autologous Tumor Cell Vaccines for Other Cancers 
Although there have not been many clinical trials reporting autologous vaccines for 
treatment of breast cancer, autologous whole tumor cell vaccines are being explored in numerous 
other cancers.  Phase I clinical trials of autologous tumor cells administered with 







, among other cancers.  As a whole, these trials 
demonstrated the safety of this vaccine with a potential for clinical benefit 
40
. Several of the 
intriguing results are highlighted to demonstrate the potential of autologous vaccines. 
An autologous tumor cell vaccine for metastatic melanoma suggests a few notable 




monthly for 5 months. A better overall survival was seen in patients with minimal disease, 
patients treated with GM-CSF or IFN-γ as adjuvant, or patients receiving an average of <7 
million cells for the first three vaccinations. The 5 year overall survival for patients with minimal 
disease was 47% compared to 13% for patients with metastatic disease. The 5 year event-free 
survival for patients treated with adjuvant cytokines was 26% compared to 0% for patients 
without adjuvant treatment. In addition, patients with <7 million cells per vaccination had a 5 
year event-free survival of 35% compared to 24% of patients with >7 million cells per 
vaccination. The vaccine produced minimal toxicity and was associated with long-term survival 
39
. 
A study done by Peng et al. showed that an autologous tumor vaccine lowered the post-
surgical recurrence rate of hepatocellular carcinoma. Patients treated with a vaccine had a 3 year 
recurrence rate of 54%, while the control group had a 72.1% recurrence rate 
38
. All of these 
vaccines were safe and well-tolerated.  
One Phase III trial using autologous whole cells was reported in colon cancer.  This trial 
consisted of autologous colon cancer cells with BCG (OncoVax) and has shown a statistically 
significant improvement in recurrence-free survival and overall survival, specifically in Stage II 
patients 
32
. Most importantly, the results showed a 61% decrease in recurrence rate with ASI 




Preclinical Studies of Autologous Whole Tumor Cell Vaccines 
Similar to clinical trials, not many pre-clinical studies have explored autologous breast 
cancer vaccines.  To our knowledge, there has not been a single lab animal study using 




tumor cells can elicit a protective immune response depending on the aggressiveness of the 
murine cancer cells. The immunogenic TS/A mammary cancer cell line has been shown to elicit 
protective immunity 
42
, while less immunogenic EMT6 mammary carcinoma cell line 
43
 and non-
immunogenic  mammary 4T1 cell line do not 
42
.  However, van Pel and Boon demonstrated in 
1982 that protective immunity could be induced in mice with non-immunogenic tumors. The key 
point was that cells used to immunize the mice must have been exposed to a DNA damaging 
agent 
44
. In addition, the lack of tumor immunogenicity was not a lack of tumor antigens, but 
rather an inability of the immune system to be stimulated due to immunosuppression 
44
. In an 
effort to overcome immunosuppression, a variety of immune system adjuvants have been 
administered with cancer cells.  By adding immune system adjuvants, most commonly GM-CSF 
and/or IL-2, a higher protective immunity is seen than by autologous cells alone 
45
.  Additionally, 
immunosuppression specifically occurs around a tumor microenvironment, but there is a 
“window of opportunity” 7-10 days after surgical removal of the tumor with decreased immune 
suppression 
46
. The knowledge gained from van Pel and Boon’s study has been applied to nearly 
every murine tumor system 
44
. By decreasing immunosuppression through addition of adjuvants 
or tumor resection, we can elicit a high protective immunity.  We know that autologous cell 
vaccines work in some murine tumors and this gives hope for successful human vaccines. 
  Although autologous whole tumor cell vaccines have shown substantial pre-clinical 
success, it is not evident why some murine cell lines elicit protective immunity while others will 
not.  We want to continue studying in the murine system to improve our understanding of what is 
the right context for a vaccine to be most effective.  Using two murine cell lines, we may 
compare the inherent immunogenic qualities and hope to determine some key factors that 




response in the murine system, we may be able to apply our knowledge to the clinical setting and 
improve clinical success.  
 
Chapter 3: Characterization of Immunogenicity in Two Breast Cancer Cell Lines 
Introduction  
Current adjuvant therapies for breast cancer are effective at prolonging survival, but still 
many patients relapse and toxicity is significant.  Therefore, we sought to develop an autologous 
whole breast cancer cell vaccine due to the favorable safety record and patient-specific approach 
of breast cancer treatment.  Autologous cells may specifically engage the immune system to 
eliminate lingering tumor cells following primary treatment.  Furthermore, because lumpectomy 
or mastectomy is indicated for the vast majority of breast cancer patients, resected tumors offer a 
readily available, patient-specific source of tumor antigen.  However, little clinical success has 
been observed due to the “self-like” quality of tumor cells, immunosuppression of tumor bearing 
patients and vaccinating in patients with extensive disease.  In this study, we used two murine 
breast cancer cell lines, 4T1 and EMT6, as the basis for the development of an autologous 
vaccine.  
First, we determined the most immunogenic way to inactivate tumor cells using two 
common cell inactivation methods, irradiation and freeze/thaw cycling. After noticing 
differences in immunogenicity between the two cell lines, surface marker expression and 
immunosuppressive cytokine secretion was measured in hopes of identifying some key 
differences between each cell line.  To further study the immunogenicity of these cell lines, a 
hybrid vaccine consisting of both cell lines was given to determine whether presence of 4T1 cells 




line, manipulations may be made to better understand what significantly influences the 
immunogenicity of each cell line.  Additionally, using the inherent immunogenic cell line, mice 
were vaccinated with varying cell doses to determine a minimum threshold of cells that will 
induce an anti-tumor immune response.  Ultimately, our goal is to create immunogenic cells that 
will elicit an anti-tumor immune response against an inherently non-immunogenic cell line. The 
following data represent a significant first step in the development of a more effective autologous 
tumor cell vaccine for use as an adjuvant therapy for breast cancer. 
 
Methods 
Mice and Tumor Cell Culture 
Female six to eight week old BALB/c mice were obtained from the Jackson Laboratory 
(Bar Harbor, ME). Mice were housed and maintained under pathogen-free conditions in 
microisolator cages.  Animal care was under compliance with the recommendations of The 
Guide for Care and Use of Laboratory Animals (National Research Council).  4T1 and EMT6 
murine mammary carcinoma cells were obtained from American Type Culture Collection 
(Manassas, VA). The 4T1 cell line was maintained in DMEM supplemented with 10% fetal 
bovine serum, 100 units/mL penicillin and streptomycin, and 2mM L-glutamine. The EMT6 cell 
line was maintained in RPMI 1640 supplemented with 15% fetal bovine serum, 100 units/mL 
penicillin streptomycin, and 2mM L-glutamine.  Cultures were maintained in a 37°C atmosphere 
with 5% CO2. 
 




4T1 and EMT6 cells were suspended in medium and irradiated at varying doses.  Cells 
were either not irradiated (0 Gy) or irradiated at 20, 40, 60, 80, or 100 Gy using a cesium 
irradiator.  Cells were plated in triplicate in a 96 well plate for each irradiation dose with 200 μl 
of medium.  After 24, 48, 72 and 96 hours of incubation, 20 μl of CellTiter 96 Aqueous One 
Solution Reagent (Promega, Madison, WI) was added to each well and incubated for an 
additional hour.  Absorbance was read at 490 nm using a Biotek Synergy 2 plate reader. This 
reagent is a colorimetric way to determine the number of viable cells in proliferation assays 
through conversion of MTS to formazan by metabolically active cells.  
 
Tumor Vaccines & Challenge 
Prior to all vaccines and challenges, mice were anesthetized with ketamine (75 
mg/kg)/xylazine (15 mg/kg) injected intraperitoneally.  Inactivated cells comprising the vaccine 
were injected subcutaneously on the right hind flank, while the live tumor cell challenge was 
administered subcutaneously on the left hind flank. Tumors were measured with calipers in two 
perpendicular diameters every 3 to 4 days. Tumor volume was calculated according to the 
equation V(mm
3
)= ½( long width * short width
2
).  Mice were euthanized by cervical dislocation 




Irradiated versus Freeze/Thawed Vaccines 
Cells were γ-irradiated at 100 Gy while suspended in medium at a concentration of 7,000 
cells/μl.  After irradiation, cells were centrifuged at 2000rpm for 5 minutes and resuspended in 
DPBS. For cell lysis, cells were subjected to 5 freeze/thaw cycles while suspended in DPBS 
using a 37°C water bath and liquid nitrogen.  Mice were injected with 1x10
6




freeze/thawed, 4T1 or EMT6 cells on days -20 and  -10 prior to challenge. On day 0, mice were 
challenged subcutaneously with 5x10
4
 viable 4T1 cells or 5x10
5
 viable EMT6 cells. 
 
Hybrid Vaccine 
4T1 and EMT6 cells were taken from in vitro culture, trypsinized, counted and 
resuspended in medium at a concentration of 7,000 cells/μl. Cells were irradiated at 100 Gy 
using a cesium irradiator and centrifuged at 2000rpm for 5 minutes, then resuspended in DPBS. 
Each cell line was then combined in one tube and mixed to ensure uniform suspension. Mice 
were injected with 1x10
6
 4T1 cells and 5x10
5 
EMT6 cells on days -20 and -10. On day 0, mice 
were challenged with 5x10
5
 EMT6 cells.  
 
Irradiated Cell Dose Vaccines 
EMT6 cells were taken from in vitro culture, trypsinized, counted and resuspended in 
medium at a concentration of 7,000 cells/μl.  Cells were irradiated at 100 Gy and centrifuged at 











 irradiated EMT6 cells on days -20 and -10. On day 0, mice were 
challenged with 5x10
5
 EMT6 cells. 
 
Detection of Secreted Cytokines 
For detection of VEGF and latent TGF-, 1x10
6
 tumor cells and irradiated tumor cells 
were plated in a 6 well plate. Supernatants were taken at 24, 48, 72 and 96 hours after plating and 
stored at -20°C (VEGF) or -80°C (TGF-) until ready for use.  The VEGF ELISA kit (R&D 




EMT6 samples. The latent TGF- ELISA kit (BioLegend, San Diego, CA) was used without 
dilutions. Each ELISA was performed following manufacturer’s protocol.  For detection of GM-
CSF, IL-6, IL-10, and MCP-1, supernatants were taken as described above and measured using a 
cytometric bead array kit (BD Biosciences, San Diego, CA) according to manufacturer’s 
instructions and analyzed using FCAP Array v3 (BD Biosciences, San Jose, CA).  
 
Antibodies and Flow Cytometry 
 Cells were suspended at a concentration of 500,000 cells /100 μl PBS per polypropylene 
tube and stained with 1μg of the appropriate antibody for an hour at room temperature.  When a 
secondary antibody conjugated to a fluorophore was needed, samples were centrifuged and 
supernatant discarded before resuspension and incubation with the secondary antibody for an 
additional hour. Antibodies used were FITC-conjugated H-2Kb, PE-conjugated I-Ad/I-Ed, PE-
Cy7-conjugated CD95, FITC-conjugated CD54, APC-conjugated CD80, and PE-conjugated 
CD86 (BD Pharmingen, San Diego, CA), ER, PR, ErbB2, PE-conjugated IgG1, and FITC-
conjugated IgG2a (Abcam, Cambridge, MA).  Samples were analyzed and median fluorescent 
intensity (MFI) was calculated using FlowJo software (BD Biosciences, San Jose, CA).  
 
In Vitro Doubling Time 
500,000 4T1 or EMT6 cells were plated in T25 flasks with 5 ml of medium and 
incubated for 8, 12, 16, 20, or 24 hours. At each time point, three flasks were removed from 
incubation. Cells were trypsinized, resuspended in 1 ml of medium, diluted in trypan blue and 








GraphPad Prism 6 was used for statistical analysis. For survival data, a log rank test was 
used to compare survival of vaccinated mice to unvaccinated mice.  For doubling time, a two 
way ANOVA was used with a Bonferroni posttest.  Means of each time point was compared for 
each cell line.  For cytokine secretion, a two way ANOVA was used with a Tukey posttest. 
Groups compared were as followed: 4T1 vs. 4T1 irradiated, 4T1 vs. EMT6, 4T1 irradiated vs. 
EMT6 irradiated, and EMT6 vs. EMT6 irradiated.  In figures, asterisks were used to denote the 
following significance levels: *p0.05; **p0.01; ***p0.001; ****p0.0001.  
 
Results 
Dose of Irradiation has no Effect on Proliferation of Tumor Cells 
Before vaccinating mice with irradiated cells, an appropriate dose of irradiation needed to 
be determined to adequately inactivate the cells in a timely manner.  In 4T1 cells, no difference 
was found between cells not irradiated and cells irradiated with any dose up to 48 hours after 
seeding (Figure 1).  Between 24 and 48 hours there was a slight increase in proliferation by all 
doses of irradiation (0-100), but after 48 hours cells that received any dose of irradiation showed 
no further increase in proliferation.  Cells that received no irradiation showed a significant 
increase in proliferation after 48 hours.  After 72 and 96 hours, there was a significant difference 
in proliferation of cells that received no irradiation and cells that received any dose of irradiation.  
Throughout all time periods of proliferation measurement, no difference was seen between any 
of the doses of irradiation. 
For EMT6 cells, all cells (not irradiated and irradiated) showed a slight increase in 




slightly significant increase in proliferation compared to cells that were irradiated (Figure 1).  
After 48 hours, cells that were irradiated no longer showed an increase in proliferation. However, 
cells that received no irradiation continued to show an increase in proliferation that was 
statistically significant from cells that received irradiation. Again, throughout all time periods of 
proliferation measurement, no difference was seen between any of the doses of irradiation.  For 
each dose of irradiation, cells continued to slowly proliferate 48 hours after incubation and then 
showed no further increase.  Based on the proliferation of both 4T1 and EMT6 irradiated cells, 





Figure 1: No difference in proliferation with varying irradiation doses.  Both 4T1 and EMT6 
cells were not irradiated (0 Gy) or irradiated with 20, 40, 60, 80 or 100 Gy and plated in a 96 
well plate with 200μl of medium.  At 24, 48, 72 or 96 hours after seeding, 20 μl of CellTiter 96 
Aqueous One Solution Reagent was added to each well, incubated for an hour and read using a 
plate reader at 490 nm to determine cell viability.  Statistical analysis was performed in 
GraphPad using a two way ANOVA with Tukey posttest.  Error bars represent SEM.  Asterisks 
were used to denote the following significance levels: **p0.01; ***p0.001; ****p0.0001. 
 
Dose of Irradiation has no Effect on Cytokine Secretion 
Since dose of irradiation showed no effect on proliferation of cells, dose of irradiation 




shown in Figure 2, there is a general increase in GM-CSF and IL-6 secretion by 4T1 cells for 
both not irradiated and irradiated cells as time increases. For both GM-CSF and IL-6, there is no 
significant difference between irradiated and not irradiated cytokine secretion until 96 hours after 
seeding.  After 96 hours, there is a small significant difference in GM-CSF secretion between no 
irradiation and 20, 40 or 80 Gy.  There is a higher significant difference between 0 Gy and 60 or 
80 Gy. No significant difference is seen in GM-CSF secretion between any of the irradiation 
doses.   
For IL-6, there is a general increasing trend in cytokine secretion as time after incubation 
increases however this increase is not as drastic as the increase GM-CSF.  A statistically 
significant difference in IL-6 secretion between irradiated and not irradiated cells is not seen 
until 96 hours after seeding.  There is a small statistically significant difference between 0 Gy 
and 60 or 80 Gy and a slightly higher statistically significant difference between 0 Gy and 100 
Gy.  Again, no difference is seen in IL-6 secretion between any of the irradiation doses.  Since 
there was no significant difference between 20-100 Gy of irradiation, we performed a literature 
search to help decide an irradiation dose for a cell based vaccine.  We chose 100 Gy based on the 







Figure 2: Cytokine secretion after varying doses of irradiation.  4T1 cells were not irradiated (0 
Gy) or irradiated with 20, 40, 60, 80 or 100 Gy and plated in a 6 well plate with 5 ml of medium.  
At 24, 48, 72 and 96 hours after plating, samples were taken from the 6 well plate and store at -
80°C.  Once all samples were collected, cytokine levels (mean  SEM) were measured with 
CBA.  Statistical analysis was performed in GraphPad using a two way ANOVA with Tukey 
posttest. Asterisks were used to denote the following significance levels: *p0.05; **p0.01. 
 
 
Irradiated Cells Provide Protection in Immunogenic Cell Line 
To determine whether irradiated or freeze/thawed cells result in better protection when 
given as a prophylactic vaccine, 1x10
6




healthy Balb/c mice 10 and 20 days before viable tumor cell challenge. Vaccinations began with 
a tumor cell dose of 1,000,000 cells, which we thought was a reasonable amount of cells that we 
may be able to extract from a tumor and later be able to vaccinate in the therapeutic setting.  
Vaccinations were performed for both the 4T1 and EMT6 cell lines. As shown in Figure 3, no 
protection was observed after vaccinations with either irradiated or freeze/thawed cells in the 
4T1 cell line.  After each vaccination with irradiated 4T1 cells, some mice developed small 
tumors which regressed after a few days (data not shown).  There was not a significant difference 
in survival of vaccinated mice and control mice, which received no vaccinations.  The median 
survival was 35, 40 and 43 days for mice vaccinated with irradiated 4T1 cells, vaccinated with 
freeze/thawed 4T1 cells and control mice, respectively.   
However, 80% of mice (4/5) vaccinated with irradiated EMT6 cells survived over 150 
days following viable EMT6 tumor cell challenge.  One mouse developed a tumor after a long 
delay between challenge with EMT6 cells and tumor growth.  The tumor first appeared 42 days 
after challenge with EMT6 cells (Figure 4).  Like the 4T1 cell line, there was no protection 
observed with freeze/thawed cells in the EMT6 cell line.  The median survival for both mice 
vaccinated with freeze/thawed EMT6 cells and control mice was 35 days.  These data confirm 
previous studies that irradiated cells provide better immune protection than freeze/thawed cells 







Figure 3:  Irradiated EMT6 cells provide protection as a prophylactic vaccine. 1x10
6
 4T1 and 
EMT6 cells were irradiated with 100 Gy or were subject to five freeze/thaw cycles with liquid 
nitrogen and a 37C water bath. Vaccines were given on day 10 and 20 prior to vaccine 
challenge. On day 0, mice were challenged with 5x10
4
 4T1 or 5x10
5
 EMT6 viable tumor cells 
and tracked for survival. Control mice were only challenged on day 0. Statistical analysis was 
performed in GraphPad using the Log Rank test. Asterisks were used to denote the following 
significance level: ***p0.001. 
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Figure 4: Irradiated EMT6 cells provide protection as a prophylactic vaccine. 1x10
6
 4T1 and 
EMT6 cells were irradiated with 100 Gy or were subject to five freeze/thaw cycles with liquid 
nitrogen and a 37C water bath. Vaccines were given on day 10 and 20 prior to vaccine 
challenge. On day 0, mice were challenged with 5x10
4
 4T1 or 5x10
5
 EMT6 viable tumor cells 
and tracked for survival. Control mice were only challenged on day 0.  Tumor volumes were 
measured every 3 to 4 days in two perpendicular directions using calipers. Statistical analysis 
was performed in GraphPad using the Log Rank test. 
 
 
EMT6 Cells Have a Faster Doubling Time than 4T1 
In order to eliminate the possibility that 4T1 tumors grew out due to a faster growth rate, 
doubling time for each cell line was calculated.  Both cell lines showed no increase in the 
number of cells prior to 12 hours after seeding.  The 4T1 cell line actually had a slight decrease 




and started to slowly increase after 12 hours of incubation.  As shown in Figure 5, as early as 16 
hours after seeding, there are significantly more EMT6 cells than 4T1 cells.  The calculated 
doubling time of EMT6 cells is 9.0 hours, while 4T1 cells have a 10.5 hour doubling time.  
Therefore, EMT6 cells grow slightly faster in vitro than 4T1 cells do. This eliminates the 
possibility that 4T1 escape protective immunity due to a faster growth rate.  
 
 
Figure 5: In vitro doubling time of 4T1 and EMT6 cells. 500,000 cells were plated in T25 flasks 
and cultured for various amounts of time. At 8, 12, 16, 20, 24 and 28 hours after seeding, flasks 
were removed from incubation, trypsinized, centrifuged and resuspended for cell counting. 
Flasks were counted in triplicate at each time point and number of cells reported is mean ± SEM.  
Statistics were calculated in GraphPad using a two way ANOVA with Bonferroni posttest.  
Asterisks were used to denote the following significance levels: *p0.05; **p0.01; ***p0.001; 
****p0.0001. 
 
Both 4T1 and EMT6 cells are classified as Triple Negative Breast Cancer 
 Since the subtype of breast cancer affects the aggressiveness and recurrence frequency of 
the disease, the molecular subtype of each cell line was classified.  Cells were stained with ER, 
PR, and HER2 antibodies and analyzed using flow cytometry.  Both 4T1 and EMT6 cells 
showed no surface expression of either hormone receptors or HER2 meaning they fall into the 




difference in immunogenicity between each cell line must not be related to the hormone 
receptors or HER2 expression.  Additionally, this means that we are working with two murine 
cell lines that are associated with poor prognosis and have a tendency to recur, but that vaccines 
may establish immune protection against even aggressive tumors that do not express any 






Figure 6: Both 4T1 (red) and EMT6 (blue) cells lines have triple negative receptor status.  Cells 
were taken from culture and suspended in polypropylene tubes at a concentration of 500,000 
cells/ 100μl PBS.  Cells were stained with anti-ER, anti-PR, or anti-ErbB2 for an hour at room 
temperature.  Following incubation, tubes were centrifuged, supernatant discarded and 
resuspended in PBS. Cells were then stained with PE anti-IgG1 or FITC anti-IgG2a for an hour 
at room temperature.  Tubes were again centrifuged and supernatant discarded a second time. 
Cells were resuspended in PBS and acquired on a BD FACSCanto II flow cytometer.  Data was 
analyzed using FlowJo_V10.  Gray shaded areas represent cells stained with only the secondary 
antibody. Numbers represent the difference in median fluorescent intensity between the control 





Surface Marker Expression of 4T1 and EMT6 Cells 
Surface molecule expression of each cell line was analyzed after a distinct difference was 
observed between vaccinating with irradiated 4T1 or EMT6 cells. The presence or absence of 
certain surface markers may influence activation and responses of effector T cells.  Each surface 
marker tested and their function is summarized in Table 1. Surface marker expression on 4T1 
and EMT6 cells was measured along with irradiated forms of each cell to understand what was 
presented to the immune system during both the vaccination and challenge.  Irradiated cells were 
found to naturally fluoresce slightly higher than normal cells and this phenomenon was taken 
into account when considering up-regulation of surface markers following irradiation.  One way 
tumors may evade the immune system is by down regulating MHC I expression on the tumor 
surface so that cytotoxic T lymphocytes (CTLs) cannot recognize the tumor cells
52
.  Both 4T1 
and EMT6 cells show similar expression of MHC I (Figure 7).  After irradiation, both 4T1 and 
EMT6 cells show a two-fold increase in ΔMFI MHC I expression.  This suggests that both cell 
lines should be able to activate CD8+ T cells.  Additionally, CTLs should be able to recognize 
4T1 cells as efficiently as EMT6 cells and that the cell lines are equally able to present antigen as 
an irradiated vaccine. 
MHC II is needed for the activation of helper T cells, which in some cases are necessary 
for the differentiation of CTLs 
52
.  MHC II is expressed by both 4T1 and EMT6 cells, and show a 
distinct up-regulation of MHC II expression 24 hours following irradiation. A slightly higher up-
regulation is seen in 4T1 cells (four-fold increase), compared to EMT6 cells (three-fold 




  Along with MHC I and II, costimulatory molecules like B7-1 and B7-2 are needed to 
initiate a strong effector T cell response 
52
.  Slight B7-1 expression is seen in 4T1 cells with a 
small up-regulation following irradiation.  EMT6 cells express almost 5 times as much B7-1 as 
4T1 cells, although the ΔMFI between the negative control and stained EMT6 cells is only 21.6 
(Figure 7).  However, irradiated EMT6 cells have an 11-fold increase in B7-1 expression 
compared to before irradiation (Figure 7).  EMT6 cells also express significantly more B7-1 
following irradiation than 4T1 cells.  As for B7-2, 4T1 and EMT6 cells have similar expression 
and show some increase in expression following irradiation.  This suggests that EMT6 cells may 
be able to induce a strong effector T cell response due to B7-1 expression during vaccination, 
while 4T1 cells are not as capable.  
Another costimulatory molecule for the activation of T lymphocytes is ICAM-1, which is 
specifically important for the costimulation of CD8+ T cells
53
.  Before irradiation, both 4T1 and 
EMT6 cells show little ICAM-1 expression with a ΔMFI of 8.4 and 12.1, respectively (Figure 7).  
However following irradiation, 4T1 cells have a 5-fold increase in ΔMFI. The ΔMFI stays the 
same before and after irradiation of EMT6 cells.  This suggests that little costimulation signal 
may be provided by ICAM-1 in the EMT6 cell line.  In the 4T1 cell line, normal cells may 
provide some costimulation while irradiated 4T1 cells provide slightly more costimulation.  
After CD8+ T cells are activated, a granule-independent mechanism may be used by 
CTLs to kill target cells.  After CTLs are activated, they express Fas ligand (FasL) which may 
then bind to a cell expressing Fas and induce apoptosis of the target cell 
52
.  We found that both 
4T1 and EMT6 cells show a distinct expression of Fas (Figure 7).  EMT6 cells show a much 
higher fluorescence intensity of Fas than 4T1 cells (8.8-fold increase).  EMT6 cells show no 




4T1 stained cells and control.  We can conclude that CTLs should be able to induce apoptosis of 
tumor cells based on Fas expression, but may be able to better eliminate EMT6 tumor cells 
through a granule-independent mechanism than 4T1 cells due to the distinctly higher Fas 
expression.  However, this is dependent on the presence of CTLs.  
 
Table 1. Summary of Surface Molecules and Functions that may Influence Immunogenicity of 
Tumor Cells. 
 
Surface Molecule Function 
MHC I Peptide presentation to CD8+ T cells 
Signal 1 for T cell activation 
MHC II Peptide presentation to CD4+ T cells  
Signal 1 for T cell activation 
B7-1 Costimulatory signal (signal 2) for T cell activation 
B7-2 Costimulatory signal (signal 2) for T cell activation 
ICAM-1 Cell-cell adhesion 
Costimulatory signal, specifically for CD8+ T cells 












Figure 7: In vitro assessment of surface molecules on 4T1 and EMT6 cells before and after 
irradiation by flow cytometry. 4T1 (left column) and EMT6 (right column) cells were stained 
with MHC I, MHC II, Fas, ICAM-1, B7-1, and B7-2 surface markers before irradiation (orange 
and blue) or after irradiation (red and green).  Cells were taken from culture and stained with 
antibody for an hour at room temperature or irradiated at 100 Gy and cultured for 24 hours 
before staining.  Gray shading represents negative control of cells (light gray) and irradiated cells 
(dark gray).  Numbers represent the difference of median fluorescence intensities (ΔMFI) 
between stained cells and the negative control (regular) or stained irradiated cells and the 
negative control (bold). This experiment was repeated three times and a representative from each 
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Secretion of Immunosuppressive Cytokines varies between Cell Lines 
Another way that tumor cells may evade the immune system is by secreting products that 
suppress the anti-tumor immune response.  In order to evaluate the immunosuppressive effects 
secreted by each cell line, GM-CSF, IL-6, IL-10, MCP-1, TGF-β and VEGF cytokine levels 
were measured using CBA or ELISA.   
High levels of GM-CSF promote expansion of myeloid derived suppressor cells 
(MDSCs)
54
.  EMT6 cells secrete no GM-CSF before irradiation and show little secretion after 
irradiation (Figure 8A).  There is no significant difference between before and after irradiation, 
and therefore no significant difference between vaccination and challenge with EMT6 cells. 
However, there is a significant difference before and after irradiation in 4T1 cells.  An increase 
in GM-CSF secretion is seen over time and this increase is even further amplified in irradiated 
4T1 cells.  There is also a difference in GM-CSF secretion between 4T1 and EMT6 cells during 
both the vaccination and challenge with viable cells. 
MCP-1 has chemotactic activity for monocytes and T lymphocytes and regulates the 
infiltration of macrophages into the tumor environment
55
.  Like GM-CSF, EMT6 cells secrete 
significantly more MCP-1 than 4T1 cells during both the vaccination and challenge with viable 
cells (Figure 8C).  Within each cell line, the irradiated cells secrete significantly more MCP-1 
than viable cells. 
One way that TGF-β exerts its immunosuppressive effects is by inhibiting proliferation 
and effector functions of T cells. TGF-β influences the development of T regulatory cells 
(Tregs), which inhibit the ability of APCs to stimulate T cells
56
.  EMT6 cells were found to 




EMT6 cells have a stronger inhibition of APCs than 4T1 cells.  No significant differences were 
seen between irradiated and non-irradiated forms of each cell line indicating that relatively the 
same amount of TGF-β is secreted during the vaccination and challenge.   
IL-6 and VEGF are other immunosuppressive cytokines that are responsible for the 
expansion and buildup of immature myeloid cells by blocking differentiation that inhibits the 
activity of CD4+ and CD8+ T cells 
57
.  The concentration of IL-6 produced by 4T1 cells 
increased slightly over time, while EMT6 mediated IL-6 production decreased over time (Figure 
8B).  Although EMT6 cells secrete a higher amount of IL-6, the difference was not significant.  
No significant difference was seen between irradiated 4T1 or irradiated EMT6 cells as well.  
There was a significant difference in IL-6 secretion before and after irradiation in each cell line.  
This indicates that there is significantly more IL-6 secreted during vaccination than during a 
challenge.  VEGF production is significantly higher in EMT6 cells than 4T1 cells both before 
and after irradiation (Figure 8E).  Unlike other cytokines, irradiation caused the down regulation 
of VEGF.  This suggests that VEGF is secreted at much lower levels during vaccinations than a 
challenge with viable tumor cells. 
We found no evidence of IL-10 secretion by either cell line (data not shown).  We found 
it interesting that EMT6 cells secrete higher amounts of 4 of the 5 immunosuppressive cytokines 
since EMT6 cells are immunogenic.  It is clear that immunogenicity is not completely influenced 
by cytokine secretion alone and that other factors, such as B7-1 expression, may be mainly 





Figure 8: Assessment of in vitro immunosuppressive cytokine secretion by 4T1 and EMT6 cells. 
Supernatants were taken from culture 24, 48, 72, and 96 hours after incubation. Cytokines GM-
CSF (A), IL-6 (B) and MCP-1 (C) were measured using CBA and TGF-β (D) and VEGF (E) 
were measured using ELISA.  For each group, the four bars represent secretion after 24, 48, 72 
and 96 hours, respectively.  Experiment was repeated 3 times and data indicates mean  SEM.  
Statistics were generated in GraphPad using a two way ANOVA with Tukey’s posttest.  





Hybrid Vaccine Inhibits Recognition of EMT6 Cells 
An inhibitory signal during vaccination may be produced by 4T1 cells that prevents 
protection and an anti-tumor immune response. To test this, mice were vaccinated with both 
irradiated 4T1 and EMT6 cells and then challenged with EMT6 cells alone to determine whether 
irradiated 4T1 cells impacted protection immunity against EMT6 cells.  As shown in Figure 9, 
protection was observed in only 40% of mice.  This is half of the survival rate from vaccinating 
with irradiated EMT6 cells alone.  Immediately after challenge, 5/5 mice grew tumors, but two 
of the mice later experienced tumor regression by day 15 and 25 after challenge (Figure 9).  The 
largest tumor volume of mice that experienced a tumor regression was 29.16 mm
3
 7 days after 
viable tumor challenge.  However, tumor size during this time was not an appropriate indicator 
of whether the mouse would experience tumor regression because two control mice and three 
vaccinated mice had tumors smaller than 30 mm
3
 7 days after challenge.  Of the vaccinated mice 
that experienced large tumor growth, there was no difference in tumor growth between the 
control and vaccinated mice.  This suggests that 4T1 cells produce some inhibitory signal that 





Figure 9: Hybrid vaccine generates little protection.  Mice (n=5) were vaccinated on days 10 and 
20 prior to tumor challenge with 5x10
5
 EMT6 and 1x10
6
 4T1 irradiated cells. On day 0, mice 
were challenged with 5x10
5
 EMT6 viable tumor cells. Control mice (n=5) were only challenged 
on day 0.  Tumor volumes were measured every 3 to 4 days with calipers in two perpendicular 
directions. (A) Survival of mice vaccinated with hybrid vaccine compared to controls. (B) Tumor 
volume of mice vaccinated with hybrid vaccine following challenge.  
 
IFN- Exposure to 4T1 cells up-regulates MHC and B7-1 
Cell-mediated immunity to tumors may be augmented by enhancing MHC and 
costimulation signals. By increasing MHC I and MHC II expression, tumor cells may be 
recognized by CTLs and recruit help from helper T cells.  Costimulatory signals from B7 
molecules may then induce an effector T cell response.  In an effort to up-regulate MHC and 




After incubation, cells were stained with antibodies or irradiated and stained with antibodies 24 
hours later. Flow cytometric analysis shows that IFN-γ treatment up-regulates surface expression 
of MHC I, II and B7-1 (Figure 10).  IFN-γ treatment affected MHC II expression the most with a 
4.4-fold increase compared to normal cells, followed by B7-1 (2.6-fold increase) and MHC I 
(1.5-fold increase).  Irradiation of IFN-γ treated 4T1 cells caused further increase in surface 
molecule expression, suggesting that IFN-γ treatment and irradiation work in a synergistic 
manner.  After IFN-γ and irradiation, MHC I and II expression on 4T1 cells (Figure 10) was 
higher than expression seen on irradiated EMT6 cells (Figure 7).  Although B7-1 expression on 
4T1 cells was increased by IFN-γ and irradiation, the ΔMFI was still lower than the MFI of 





Figure 10: IFN-γ up-regulates surface MHC II and B7-1 of 4T1 cells in vitro.  Cells were 
exposed to 1 ng/ml IFN- γ for 24 hours in vitro.  Following incubation with IFN- γ, cells were 
taken from culture and stained with antibody for an hour at room temperature (pink) or irradiated 
with 100 Gy and cultured for 24 hours before staining (purple).  Gray shading represents 
negative control of cells (light gray) and irradiated cells (dark gray).  Numbers represent the 
difference of median fluorescence intensities (ΔMFI) between stained cells and the negative 





Protection from Irradiated Cells is Dose Dependent 
A minimum threshold of irradiated cells required to induce immune memory was 













 irradiated EMT6 cells on days 10 and 20 prior to viable EMT6 tumor 
challenge.  After the challenge, mice were tracked for tumor growth and tumors were measured 
every 3 to 4 days.  With this tumor model, the data suggests a minimum vaccine dose of 250,000 
cells is required to induce immune memory.  Mice that were vaccinated with lower than 250,000 
cells experienced small tumor formation immediately after viable tumor cell challenge, but the 







, respectively.  Although these mice experienced tumor 
regression, we did not find it positive that mice experienced any tumor formation.  Vaccinating 
with 250,000 irradiated EMT6 cells was the only vaccination dose that no tumor growth was 
observed so this was determined to be the minimum threshold to completely inhibit tumor 
formation.   
For vaccination doses higher than 250,000 irradiated cells, 1/5 mice for each dose 
experienced tumor growth and were sacrificed once the tumor reached 2000 mm
3
.  The mouse 
vaccinated with 1x10
6
 irradiated cells showed a delayed tumor growth starting 42 days after 
challenge, while the mouse vaccinated with 5x10
5
 irradiated cells showed no delay and 
experienced tumor growth similar to control mice.  Larger sample sizes are needed before 















 (n=3), or 3.12x10
5
 (n=3) 
irradiated EMT6 cells. On day 0, mice were challenged with 5x10
5
 EMT6 viable tumor cells. 





Autologous cells as a form of breast cancer immunotherapy have numerous advantages 
over current adjuvant therapies including patient specificity, minimal toxicity, and a potential of 
maintaining long term immunity.  Since tumor resection is indicated for the majority of breast 
cancer patients, a source of tumor antigen is readily available for vaccination in the adjuvant 
setting.  A vital component of inducing protective immunity from cancer using cellular vaccines 
is first inactivating tumor cells.  Two common methods of inactivating cells are irradiation and 
freeze/thaw.  We found a distinct difference in the ability of irradiated and freeze/thawed cells to 
establish immune memory.  In an immunogenic cell line, prophylactic vaccination with 
irradiated cells elicited protective immunity in 80% of mice, compared to 0% protection using 




.   The 
difference in protective immunity between each antigen form indicates a preference in the way 
antigen is presented to the immune system.  When administering cellular vaccines, inactivating 
cells with irradiation will elicit stronger responses than freeze/thawed cells.   
Although we did not analyze any further why irradiated cells provided better protection, 
others have reported the in vivo effects and mechanistic results of vaccinating with both forms of 
antigen.  The in vivo effects of each vaccine, as reported by Scheffer et al., show that 
freeze/thawed cells failed to induce a potent immune response that may be due to the infiltration 
of various cells. Irradiated cells were able to bring strong infiltration of CD4+, CD8+, and 
dendritic cells (DCs) at the injection site while freeze/thawed cells had no presence of these cells 
10 days past injection and instead resulted in a strong macrophage infiltration 
50
.  Furthermore, a 
detailed in vivo mechanistic study with irradiated and freeze/thawed cells reports that both forms 




CD8+ T cells primed by irradiated cells expand and express full effector function, CD8+ T cells 
primed by freeze/thawed cells do not accumulate and a smaller proportion become functional 
58
.  
The accumulation of different cells, particularly the lack of CD8+ accumulation by 
freeze/thawed cells, may be responsible for the differences in immune protection.   
While vaccination with irradiated cells from an immunogenic cell line (EMT6) is able to 
elicit protection, no protection was observed when vaccinating with a non-immunogenic cell line 
(4T1).  There must be a difference between 4T1 and EMT6 cells that prevents 4T1 cells from 
inducing an anti-tumor immune response.  Some surface markers, such as those used to classify 
breast cancer subtype, may have an indirect influence on the anti-tumor immune response by 
indicating aggressiveness of the cancer and potential of breast cancer recurrence.  Presence of 
hormone receptors and/or HER2 influences the prognosis and treatment options available to 
breast cancer patients.  Both 4T1 and EMT6 cells lack the ER, PR, and HER2 and therefore are 
classified as TNBC. This subtype is known to have aggressive characteristics such as early 
relapse and decreased survival. However, there is a lack of therapeutic treatments for TNBC due 
to the absence of these receptors which may influence the survival trend 
59
.  Since both the 
immunogenic and non-immunogenic cell lines are triple negative for the ER, PR, and HER2, we 
can assume that while these markers may influence the aggressiveness of cancer, they do not 
determine immunogenicity.  Protective immunity elicited by vaccinating with EMT6 cells 
demonstrates the presence of immunogenic antigens other than HER2.  Approximately only 40% 
of women have HER2 positive breast cancer (Luminal B and HER2+ subtypes) and will benefit 
from HER2 targeted therapy.  Autologous cells may serve as a promising treatment option for all 
breast cancer patients, but notably women with TNBC, due to presence and immunogenicity of 




Surface marker expression and cytokine secretion by each cell line may directly influence 
the anti-tumor immune response by evading recognition by T cells or inhibiting their activation.  
Tumors may down regulate MHC I to evade recognition, and therefore apoptosis, by CTLs.  
Tumors may also lack MHC II expression, which is needed to activate helper T cells and aid in 
differentiation of CTLs
52
.  Both the 4T1 and EMT6 cell lines express MHC I and II at low levels 
and should be able to carry out these processes.   
Costimulators are also needed to initiate T cell responses
52
.  The best characterized 
costimulatory molecules are B7-1 and B7-2 which bind to CD28 on a naïve T cell.  Expression 
of B7 is imperative because through multiple mechanisms, engagement of CD28 induces 
differentiation of effector and memory cells 
52
.  The most notable difference observed between 
the surfaces of each cell line was the up-regulation of B7-1 in EMT6 cells after irradiation, while 
irradiated 4T1 cells only saw a small up-regulation.  This suggests that EMT6 cells may provide 
a strong costimulatory signal through the B7-1 molecule and enhance T cell activation, while 
4T1 cells are not.   
IFN-γ is a known regulator of B7 molecule expression on APCs.  In the 4T1 tumor 
microenvironment, there is not enough IFN-γ in the tumor microenvironment to up-regulate 
genes until 15 days after implantation
60
, after tumor cells have already metastasized.  Gene 
transfer of MHC II or B7-1 reduces metastases and tumorigenicity of 4T1 cells 
61
.  Treatment of 
4T1 cells with only 1ng/ml IFN-γ for 24 hours at least doubles MHC II and B7-1 expression and 
a further increase is seen after irradiation.  However, increase in B7-1 expression still is not 
comparable to B7-1 expression on irradiated EMT6 cells.  It is not clear how much B7-1 
expression is needed to benefit the anti-tumor immune response or if any protection would be 




Once CTLs are activated, they may perform granule-independent killing, through 
Fas/FasL interaction, or granule-dependent killing, through ICAM-1/LFA-1 interaction.  Once 
FasL on the surface of the CTL attaches to the death receptor Fas on the target cell, apoptosis is 
initiated in the Fas expressing target.  Both 4T1 and EMT6 express Fas and show an up-
regulation following irradiation suggesting that CTLs, which express FasL, should be able to 
eliminate both tumor cell lines through a granule-independent mechanism as long as CTLs are 
present.  ICAM-1 is a cellular adhesion molecule and functions as a costimulator, specifically for 
CD8+ cells.  ICAM-1 is hardly expressed on 4T1 or EMT6 cells, but irradiation results in an 
increase in ICAM-1 expression on 4T1 cells.  Since both cell lines express little ICAM-1 and 
high levels of Fas, we assume that each cell line is likely killed in a granule-independent manner. 
Immunosuppressive cytokine secretion is another way that tumor cells may escape 
immune defenses.  Cytokines can influence the immune system to promote immunosuppression 
and tumor growth by inhibiting T cell activation and regulating expansion, recruitment and 
differentiation of various cells.  MCP-1 regulates the infiltration of macrophages in the tumor 
environment and also influences T cell differentiation through IL-4, which inhibits a Th1 CD4+ 
T cell response critical for the elimination of cancer 
55
.  TGF-β also inhibits a Th1 response, 
along with inhibiting NKs, CTLs, and macrophages that results in prevention of anti-tumor 
immunity 
56, 62
.  However, TGF-β has both tumor promoting and tumor suppressive effects, 
which is dependent upon the stage of cellular transformation. As a tumor suppressor, TGF-β 
increases apoptosis of cancer cells and inhibits expression of growth factors, including GM-CSF 
56, 63
.   IL-6 and VEGF are other immunosuppressive cytokines that are responsible for the 
expansion and buildup of immature myeloid cells by blocking differentiation that inhibits the 
activity of CD4+ and CD8+ T cells 
57




antigen-presenting DCs and is associated with the accumulation of tumor associated 
macrophages
64
.  We show that EMT6 cells produce higher amounts of each immunosuppressive 
cytokine tested than 4T1 cells, except for GM-CSF.  We found it interesting that the 
immunogenic cell line actually secretes more immunosuppressive cytokines than the non-
immunogenic cell line.  It is not clear if there is a dominant immunosuppressive cytokine or if 
certain cytokines synergize to create a more suppressed immune system.  Since GM-CSF 
production is the major difference between each cell line, future studies will focus on the knock-
out or knock-in of GM-CSF in 4T1 and EMT6 cells, respectively. 
GM-CSF production is a double-edged sword.  In the B16 melanoma mouse model, GM-
CSF was shown to be the most potent stimulator of anti-tumor immunity out of IL-2, IL-4, IL-5, 
IL-6, IFN-g, IL-1RA, ICAM, CD2, and human TNF-a 
45
.  Vaccines in conjunction with GM-
CSF as an adjuvant result in enhanced tumor antigen presentation by dendritic cells and 
macrophages 
65
.  However, GM-CSF has also been reported to promote the expansion of MDSCs 
in the mouse, characterized by the CD11b and Gr1 markers 
54
.  Upon investigation, GM-CSF 
gives either a stimulating or inhibitory signal to the immune system depending on the level of 
cytokine secretion. In a model by Serafini, the upper threshold of stimulating the immune system 
through GM-CSF secretion was 206 pg/ml 
54
.   We show that not only do 4T1 cells produce a 
significantly greater amount of GM-CSF than EMT6 cells both before and after irradiation, but 
that the secretion level is well above the 206 pg/ml upper threshold. Therefore, 4T1 cells may be 
recruiting a large number of MDSCs resulting in immunosuppression rather than immune 
stimulation.  
We confirmed production of an inhibitory signal by 4T1 cells with creation of a hybrid 




EMT6 cells, 60% of mice developed a tumor.  Importantly, immediately after the challenge with 
EMT6 cells all mice grew a tumor, but two mice later had tumor regression.  Half of the 
protection is observed when vaccinating with both cell lines rather than vaccinating with EMT6 
cells alone (40% vs. 80%).  Therefore, an inhibitory signal must be produced by 4T1 cells during 
vaccination to prevent the recognition of EMT6 cells.  It is not clear what the 
immunosuppressive signal is that prevents recognition of EMT6 cells.  We predict that over 
production of GM-CSF takes some role in the immunosuppressive signal since this is the only 
immunosuppressive cytokine that we tested that EMT6 cells did not produce.  We are not sure 
whether GM-CSF is acting alone or synergizing with the other immunosuppressive cytokines or 
surface molecules to prevent immune protection from 4T1 cells and EMT6 cells in the hybrid 
vaccine. 
Secretion of large amounts of immunosuppressive cytokines leads to splenomegaly, 
which is observed due to massive granulocytic infiltrates 
66
. These infiltrates, such as MDSCs, 
are an obstacle to active immunotherapy because they block the activation of tumor reactive T 
cells and induce accumulation of Tregs 
67
, another splenocyte population associated tumor-
associated immune suppression 
46
.  Almost 50% of cells in the spleen of a 4T1 tumor bearing 
mouse are CD11b+Gr1+ 
66
, whereas the same cell population in the spleen of an EMT6 tumor 
bearing mouse is 20%
57
.  The lower concentrations of MDSCs in the spleen of EMT6 mice may 
partly be attributed to the lack of GM-CSF secretion. 
Additionally, there is a minimum limit in which irradiated cells are able to confer 
immunity and in the EMT6 model the limit is 250,000.  In order to administer a successful 
therapeutic vaccine at least 250,000 cells must be obtained following tumor resection in the 






 tumor cells per 0.5 g of tumor.  Therefore, we are able to obtain more than 
enough cells needed for a therapeutic vaccine.  Therapeutic studies are critical for future studies 
for a more accurate representation of the clinical setting.  
Our studies confirm that irradiated cells serve as a better vaccination than freeze/thawed 
cells and provide a possible explanation for the lack of protection from 4T1 cells when 
administered as a vaccine.  Based on the differences in the immunogenic profile of each cell line, 
a direction for future studies involves the manipulation of 4T1 cells through changes in surface 
molecules and cytokine secretion in hopes of developing a more immunogenic tumor.   
 
Chapter 4: Future Perspective 
Introduction 
A majority of breast cancer patients will undergo surgery following diagnosis of breast 
cancer.  Following surgery, majority of patients are given adjuvant therapy in an attempt to 
eliminate tumor cells that may have disseminated from the primary tumor.  Adjuvant therapy, 
such as chemotherapy, radiation therapy, hormonal or targeted therapy, have toxic side effects 
and benefit only a subset of patients.  Still, 1 out of 5 patients go on to have a recurrence after 10 
years.  Since the majority of breast cancer deaths are due to the recurrence and progression of 
non-metastatic disease, an intervention is needed that promotes the immune system to eradicate 
lingering tumor cells after surgery.  The use of autologous whole tumor cells as adjuvant therapy 





Future Pre-Clinical Studies 
Pre-clinically, we have demonstrated the effectiveness of an autologous whole cell breast 
cancer vaccine using a murine model.  In the EMT6 cell line, 80% of mice vaccinated with 
autologous cell later reject a challenge with live cells.  However, vaccinations were only 
successful in an immunogenic cell line.  Mice vaccinated with irradiated 4T1 cells, showed no 
protection or delay in tumor growth.  Using the differences observed between the immunogenic 
profiles, each cell line may be manipulated to change expression of surface molecules or 
secretion of cytokines in an effort to understand their role in immunogenicity.  The advancement 
of immunotherapy for 4T1 cells is dependent on the understanding of various characteristics of 
the immunogenic profile and the influence they have on immunogenicity.  
By altering the immunosuppressive cytokine profile and therefore the various cell 
infiltrates in the spleen and tumor, we may be able to change the “immunogenic profile” of a 4T1 
tumor into an immunogenic tumor that is capable of immune protection.  We believe that down 
regulation of GM-CSF secretion shows the most potential in eradicating the immunosuppressive 
signal secreted by 4T1 cells.  EMT6 cells secrete no GM-CSF and other studies have shown that 
GM-CSF levels above 206 pg/ml induce a suppressive immune signal, so we believe that 
significantly lowering or knocking out GM-CSF in 4T1 cells will promote the anti-tumor 
immune response.  Significant, but not total, knockout of GM-CSF in 4T1 cells results in 
reduction of CD11b+Gr1+ splenocytes 
68
.  Since MDSCs are a hindrance to immunotherapy, by 
reducing GM-CSF and therefore MDSCs accumulation, the immune system may be able to elicit 
some tumor protection.  Another study may include a gene encoding GM-CSF to be inserted in 




Other immunosuppressive cytokines may also be knocked out in 4T1 cells. Treatment of 
a 4T1 tumor with an anti-TGF-β antibody also showed a decrease of CD11b+Gr1+ splenocytes.  
When mice were treated therapeutically with an anti-TGF-β antibody, approximately 30% of 
mice survived
56
.  Future studies may explore a knockout of TGF-β in a prophylactic vaccine of 
4T1 cells alone or in combination with GM-CSF knockout.  
In addition to cytokine secretion, surface molecules may influence the anti-tumor 
immune response.  Gene transfer of MHC II and B7-1 reduces the metastatic and tumorigenic 
capability of 4T1 cells.  Vaccinating with 4T1 cells that have been transduced with MHC II 
and/or B7-1 may increase initiation of T cell responses supplying a stronger immune response 
following challenge.  We show that IFN- up-regulates MHC I, II and B7-1 in vitro and the 
increase in expression of these surface markers may be enough to elicit some tumor protection.   
Additionally, vaccinating with a B7-1 knockout in the EMT6 cell line may also indicate the 
influence of B7-1 in immunogenicity of tumor cells.  
 In addition to the future studies mentioned above, therapeutic vaccinations may be 
implemented to more accurately represent the current clinical setting.  After surgery, tumor cells 
may be left behind because either the whole tumor may not have been removed or tumor cells 
have already travelled to other local or distant parts of the body.  Prophylactic vaccinations do 
not take into account existing tumor cells, and possible immunosuppression, while therapeutic 
vaccinations do.  Since the primary treatment of breast cancer is surgery, it is important to study 





Implementation in the Clinic 
Clinically, less success has been observed compared to pre-clinical models.  Three key 
questions need to be addressed regarding development autologous tumor cell vaccines to 
improve clinical results. First, immunogenicity of the cells will need to be improved through 
better delivery and inactivation of the cells. It has been shown pre-clinically that GM-CSF is a 
strong immune system stimulator. However, GM-CSF and IL-2 works synergistically to provide 
an immune response stronger than each adjuvant individually
69
. Different adjuvant formulations 
should be investigated to determine what best stimulates a patient’s immune system.  For 
example, 67% of mice treated intratumorally with chitosan/IL-12 prior to tumor resection 
became tumor free.  All mice were later protected following a challenge with viable 4T1 cells, 
suggesting that this treatment made 4T1 cells immunogenic. 
Second, a signature of what makes a tumor immunogenic would be helpful in identifying 
patients that will benefit from vaccination. Tumor antigen expression, number of T cell 
infiltrates, immunosuppression all could have an impact on how well a patient responds to 
vaccination. For example, establishment of an immune score based on cytotoxic and memory T 
cells in colorectal cancer has shown to improve prediction of tumor recurrence
70, 71
.   An immune 
score should be applicable to most human tumors
72
, including breast cancer.  T-cell infiltration in 
breast cancer has been associated with favorable prognoses
73, 74
, although extent of recurrence-
free and overall survival with high T-cell infiltration is not known. By identifying patients that 
respond to vaccination and characterizing their tumor and tumor microenvironment, we may be 
able to determine patients with a high-risk of recurrence and patients that may benefit from 




to manipulate tumor cells for patients who originally would not respond as well to 
immunotherapy in an effort to increase immune system activation. 
Third, a standardization of preparing vaccines is important for consistent results. Once a 
tumor has been removed from a patient, standard protocols are needed for dissociating the tumor. 
Common methods include enzymes such as DNAse and collagenase. Then cells must be either 
cryopreserved or cultured for the duration of immunotherapy. Finally, cells must be prepared to 
give back to the patient. Often cells are either irradiated or treated with Mitomycin C. The 
numerous methods of preparing autologous tumor cells must be optimized so that they give the 
greatest immune response and give reliable results. After preparation, the location of 
administration and duration of the immunotherapy should be standardized as well. By solving 
these three key challenges, autologous whole tumor cell vaccines may produce clinically 
significant results that build on the success of improved over-all and recurrence free-survival that 
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Freeze/Thaw cells with -80°C Ethanol 
 
In an effort to vaccinate mice with cell lysates, cells were subjected to 5 freeze/thaw cycles while 
suspended in DPBS using a 37°C water bath and -80°C 70% ethanol and distilled water mixture.  
Mice were injected with 1x10
6
 freeze/thawed 4T1 (n=4) or EMT6 (n=4) cells.  However, this 
model did not serve as an appropriate method for freeze/thawing cells. Shortly after vaccination, 
mice began to grow tumors suggesting that a significant number of cells survived the freeze/thaw 
cycles.  100% of mice injected with 4T1 cells grew tumors, while 75% of mice injected with 





Triple Enzyme Mouse Tumor Digestion 
Preparation 
10X Triple Enzyme Stock Solution: 
Collagenase 1 g f.c. [10 mg/ml] 
Hyaluronidase 100 mg f.c. [1 mg/ml] 
DNase 20,000 Units f.c. [200 mg/ml] 
HBSS 100 ml 
Sterile filter (0.22 m) and store 5 ml aliquots at –20°C. 
Thaw at RT (NOT 37°C) before use. 
Procedure 
1. Remove tumor and place into a 60 or 100 mm petri dish and add 5-10 ml HBSS 
2. Quickly mince tumor into fragments small enough to be pulled into a 5 ml pipette without 
getting stuck. 
3. Transfer to 50 ml conical tube. 
4. Rinse petri dish with up to 40 ml HBSS and transfer to tube. Total volume in tube should be 
45 ml (if not, bring up to volume with HBSS). 
5. Add 5 ml 10X Triple Enzyme Mix to the tube and place on rotisserie for 1 hr. 
6. Pass cells through 70 μm nylon mesh filter unit into a second 50 ml conical tube.  
7. Pellet cells at 1200 rpm for 8 min. 
8. Aspirate supernatant and resuspend cells in 15ml cell medium. 
9. Carefully layer the cell suspension on top of 15ml Histopaque. 
10. Centrifuge the sample at 400xg for 30 minutes with acceleration set at “1” and deceleration 




11. At the end of the spin, an opaque layer of cells should be observed at the interphase of the 
histopaque and cell medium layers. Transfer these live cells carefully to a 15ml tube. Bring total 
volume to 15ml with cell medium if needed. 
12. Centrifuge 15ml tube at 2000rpm for 10 minutes. 
13. Aspirate supernatant and resuspend cells in 1ml medium.  
14. Count cells. 
